9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Dasatinib in Resectable Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Dasatinib in Resectable Malignant Pleural Mesothelioma

Dasatinib in Resectable Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 60

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Modulation of biomarker p-Src Tyr419 expression,  Progression-free Survival,  ,

Interventions: Dasatinib,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 2019

Completion Date: March 2019

Last  Posted Date: September 27, 2018

Location: University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00652574

Was this article helpful?
Dislike 0